US DMFs Filed
USA (Orange Book)
Company has granted Taro an exclusive license to market, sell and distribute in Canada, Desvenlafaxine Extended-release Tablets in the 50 mg and 100 mg strengths approved for sale in the Canadian market by the Pharmaceutical Drugs Directory (PDD) of Health Canada.
Lead Product(s): Desvenlafaxine Succinate
Therapeutic Area: Psychiatry/Psychology Product Name: Desvenlafaxine-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Intellipharmaceutics Corp.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 16, 2022